EMG
ALNY icon

ETF Managers Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

ETF Managers Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$2.08M Sell
10,382
-742
-7% -$156K 0.07% 150
2022
Q4 		$2.64M Sell
11,124
-90
-0.8% -$19.2K 0.12% 97
2022
Q3 		$2.25M Sell
11,214
-23,965
-68% -$4.57M 0.07% 145
2022
Q2 		$5.12M Buy
35,179
+18,279
+108% +$2.59M 0.15% 126
2022
Q1 		$2.79M Sell
16,900
-5,379
-24% -$819K 0.06% 177
2021
Q4 		$3.81M Sell
22,279
-3,423
-13% -$636K 0.08% 176
2021
Q3 		$4.56M Buy
25,702
+6,822
+36% +$1.28M 0.09% 154
2021
Q2 		$3.13M Sell
18,880
-7,892
-29% -$1.16M 0.05% 186
2021
Q1 		$3.62M Buy
26,772
+7,069
+36% +$1.06M 0.06% 153
2020
Q4 		$2.58M Buy
19,703
+1,380
+8% +$184K 0.06% 174
2020
Q3 		$2.66M Buy
18,323
+7,966
+77% +$1.13M 0.08% 142
2020
Q2 		$1.53M Buy
10,357
+7,415
+252% +$1,000K 0.05% 152
2020
Q1 		$320K Buy
2,942
+300
+11% +$34.6K 0.01% 285
2019
Q4 		$303K Buy
2,642
+607
+30% +$60.5K 0.01% 371
2019
Q3 		$165K Sell
2,035
-73
-3% -$5.78K 0.01% 495
2019
Q2 		$150K Buy
2,108
+906
+75% +$69.5K ﹤0.01% 515
2019
Q1 		$112K Buy
1,202
+116
+11% +$9.7K 0.01% 485
2018
Q4 		$79K Buy
1,086
+147
+16% +$11.3K ﹤0.01% 520
2018
Q3 		$82K Buy
939
+98
+12% +$9.86K ﹤0.01% 531
2018
Q2 		$66K Sell
841
-528
-39% -$52.4K ﹤0.01% 387
2018
Q1 		$139K Buy
1,369
+170
+14% +$21.9K 0.01% 241
2017
Q4 		$158K Buy
1,199
+170
+17% +$21.4K 0.01% 218
2017
Q3 		$121K Buy
1,029
+85
+9% +$7.25K 0.01% 135
2017
Q2 		$75K Buy
+944
New +$60.3K 0.01% 206
2016
Q1 		$23K Buy
+450
New +$29.9K 0.02% 439

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ETF Managers Group's ALNY Position: Q1 2023 in Review

ETF Managers Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 6.7% in Q1 2023, selling an estimated $156K and leaving 10,382 shares worth $2.08M. The position accounts for 0.07% of the portfolio, ranked #150.

ETF Managers Group first reported a position in ALNY in Q1 2016 and has held it in 25 quarters since. The position peaked at $5.12M in Q2 2022. 477 funds tracked by Wall St. Rank hold ALNY as of Q1 2023.

  • ETF Managers Group held 10,382 shares of Alnylam Pharmaceuticals worth $2.08M as of Q1 2023.
  • ETF Managers Group sold 742 Alnylam Pharmaceuticals shares in Q1 2023, an estimated $156K.
  • Alnylam Pharmaceuticals made up 0.07% of ETF Managers Group's portfolio in Q1 2023, its #150 holding.
  • ETF Managers Group first reported a position in Alnylam Pharmaceuticals in Q1 2016 and has held it in 25 quarters since.
  • ETF Managers Group's Alnylam Pharmaceuticals position peaked at $5.12M in Q2 2022.
  • 477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.